A hemagglutination-inhibition test for the determination of vaccinia antibodies in serum was first described by Nagler.5 It has been used extensively by us in a standardized form.2 Collier8 has utilized a modification of the method in his study of adults. The present report deals with the determination of the titre of vaccinia antibodies in the sera of 182 mothers at term and in the cord blood of their newborn offsprings. Of the mothers, 102 had been vaccinated within the past five years, while 80 had been vaccinated more than five years ago.
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METHODS
A standardized procedure of determining vaccinia hemagglutination-inhibition antibodies in serum has been described previously.2 A suspension of vaccinia-infected allantoic membranes is used as the antigen. Fowl cells susceptible to hemagglutination with the vaccinia-variola group of viruses are utilized in a concentration of 0.5 per cent in Alsever's solution. A single hemagglutinating unit is defined as that dilution of the antigen which produces definite hemagglutination of 0.25 cc. of a 0.5 per cent suspension of vaccinia-sensitive fowl cells. The specificity of this reaction is shown as follows:
(i) Serum of vaccinated individuals inhibits this agglutination to a reproducible titre.
(ii) There is failure of inhibition of agglutination by sera of non-immune rabbits. Sera for antibody determination are diluted in 10 Kahn tubes in two-fold dilution in 0.85 per cent saline solution (1:5 to 1:2560). The volume of diluted serum is 0.25 ml. To the serum dilutions, 0.25 ml. of antigen dilution containing two hemagglutinating units is added. Known positive and negative control sera are included. An antigen control is set up in which the antigen dilution used in the test is diluted in saline. Racks are shaken and incubated for one hour at 350 to 370 C. Then 0.25 ml. of 0.5 per cent fowl cell suspension is added, the racks shaken and allowed to stand at room temperature until the cells are settled. After one hour, the pattern of sedimented cells is examined. The greatest serum dilution which produces complete inhibition of agglutination is recorded as the hemagglutination-inhibition titre of that serum. The tube containing this dilution should present the same pattern as a control tube with 0.25 ml. of vaccinia-sensitive red cell suspension and 0.5 ml. of saline. The complement-fixation titres of these infants is also significantly higher than those of their mothers. their newborns are identical or differ by one dilution in either directionthe latter differences being considered to be within the error of the test.
In the group shown in Chart 1, 41 out of 102 of the newborn infants have titres significantly higher than their mothers, while only four of the 102 are significantly lower. The results shown in Chart 2 indicate that 30 out of 80 have titres significantly higher than their mothers, while only one of the 80 is significantly lower.
In order to test whether these higher titres, in fact, represent specific antivaccinia substance, complement-fixation tests also were performed on the sera of 141 of the infants and their mothers. Chart 3 shows that, in general, newborn infants who have hemagglutination-inhibition titres higher than their mothers also show higher complement-fixation titres. Fairly good 33(J correlation between these two very distinct antibodies is apparent, indicating presence of a specific immune substance.
DISCUSSION
The findings of consistently higher antibody titres in the blood of newborn infants, when compared to their own mothers, are of great interest and are not readily explained. They suggest that actual immune substance is being measured and this tends to be borne out by the preliminary experiments subsequently described. The higher concentration may be explained on the basis of concentration in the placenta and corresponding diaplacental transfer. This has been discussed by Doerr.' Such passively transferred and, perhaps, enhanced immunity immediately following smallpox vaccination of the mother may have definite clinical significance in pediatrics. SUMMARY 1. A comparison of the hemagglutination-inhibition titres of 182 mothers at term and their newborn infants reveal consistently higher titres in the infants in a significant number of cases.
2. Mothers vaccinated within the past five years have higher titres than those vaccinated earlier.
3. Infants of mothers vaccinated within the past five years have significantly higher titres than those whose mothers were vaccinated more than five years ago.
II. RESPONSE TO VACCINATIONS
A preliminary attempt to evaluate the significance of occasional high levels of hemagglutination-inhibition antibody titres in cord blood was made. Four newborn infants were vaccinated on the fifth day of life. Two of these had had very high titres in the serum, while the other two had had very low titres. The two infants (A.R. and B.D.) with high antibody titres failed to show any skin reactions at the site of vaccination, despite three attempts at vaccination. The two (R.W. and C.O.) with low antibody titres had a "vaccinia-take," with maximum skin reaction occurring on the tenth day after the vaccination. Figure 2 shows the serologic response of these four infants.
At approximately six months of age, repeat vaccinations were performed on three of the four infants. Prior to revaccination infant A.R. had a residual antibody titre of 1:40, while B.D. had a titre of 1:160, and infant C.O. had a titre of 1:10. Revaccination of these three infants produced no allergic or immune early response in patients A.R. and B.D., and resulted in an early sensitivity response in infant C.O. followed by a typical vaccinoid reaction, maximal on the sixth day.
Infants A.R. and B.D. developed a reaction maximal on the fifth and sixth days, respectively. Had it not been for the absence of an early sensi-tivity type of reaction, indicating a lack of previous antigenic experience to the virus, these reactions would undoubtedly be called vaccinoid. However, in the absence of this type of sensitivity reaction and the known findings of a high titre of passively acquired antibodies, it is suggested that these were modified primary "vaccinia takes." A third vaccination performed on these two children (A.R. and B.D.), at the age of one year, resulted in a sensitivity type or is not seen in unvaccinated infants but is present virtually in all revaccinated children.
In the absence of an early sensitivity response suggestive of previous antigenic experience, accelerated vaccinia resembling a vaccinoid reaction may represent modification of the infection by passively acquired immunity present in the tissue. SUMMARY 1. Two newborn infants with high hemagglutination-inhibition antibody titres in their sera could not be successfully vaccinated in the first two weeks of life and these may represent instances of actual "no takes." 2. Two newborn infants with low hemagglutination-inhibition antibody titres in their sera were successfully vaccinated in the first week of life and demonstrated a rise in antibody titre.
3. At the age of six months repeat vaccination of the two infants with high titres resulted in a skin reaction maximal on the fifth and sixth days, respectively, in the absence of an earlier sensitivity type of reaction. This suggests that no previous antigenic experience had occurred and that the present response was, in fact, a modified vaccinia or accelerated primary response. Serologic data on these patients have been presented.
